4th NOAC ‘Lixiana’ landed in 4 of ‘Big 5’ hospitals

A series of news about the 4^th NOAC ‘Lixiana(edoxaban)’ to land in general hospitals have continuously followed.

According to the industry concerned on the 13^th, Lixiana, the new oral anti-coagulant(NOAC) jointly sold by Daiichi Sankyo and Daewoong Pharmaceutical, succeeded in landing in 4 of the so-called ‘Big 5’ hospitals: Seoul National University Hospital, Severance Hospital, Samsung Medi...